These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37666293)

  • 21. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
    Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
    Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
    Capula M; Perán M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
    Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
    Shevchenko I; Karakhanova S; Soltek S; Link J; Bayry J; Werner J; Umansky V; Bazhin AV
    Int J Cancer; 2013 Jul; 133(1):98-107. PubMed ID: 23233419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
    Phua LC; Goh S; Tai DWM; Leow WQ; Alkaff SMF; Chan CY; Kam JH; Lim TKH; Chan ECY
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):277-289. PubMed ID: 29196965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
    Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
    Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
    Zhu YX; Li CH; Li G; Feng H; Xia T; Wong CH; Fung FKC; Tong JH; To KF; Chen R; Chen Y
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):811-828. PubMed ID: 32615164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
    Binenbaum Y; Fridman E; Yaari Z; Milman N; Schroeder A; Ben David G; Shlomi T; Gil Z
    Cancer Res; 2018 Sep; 78(18):5287-5299. PubMed ID: 30042153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
    Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M
    Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
    Du J; Gu J; Li J
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
    Principe DR; Narbutis M; Kumar S; Park A; Viswakarma N; Dorman MJ; Kamath SD; Grippo PJ; Fishel ML; Hwang RF; Thummuri D; Underwood PW; Munshi HG; Trevino JG; Rana A
    Cancer Res; 2020 Aug; 80(15):3101-3115. PubMed ID: 32238357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
    Qian W; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W
    Life Sci; 2018 Sep; 208():253-261. PubMed ID: 30053447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Barriers and opportunities for gemcitabine in pancreatic cancer therapy.
    Beutel AK; Halbrook CJ
    Am J Physiol Cell Physiol; 2023 Feb; 324(2):C540-C552. PubMed ID: 36571444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
    Yu X; Liu W; Wang Z; Wang H; Liu J; Huang C; Zhao T; Wang X; Gao S; Ma Y; Wu L; Li X; Yang S; Hao J
    Cancer Lett; 2021 Oct; 519():289-303. PubMed ID: 34302921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma.
    Wang M; Hu Q; Huang J; Zhang F; Yao Z; Shao S; Zhao X; Liang T
    Adv Healthc Mater; 2023 Aug; 12(20):e2203264. PubMed ID: 36971070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
    Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
    Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
    Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
    PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.